Baltimore, MD, United States
Baltimore, MD, United States

Ameritox is a company that provides physicians with urine drug monitoring and reporting services. Headquartered in Baltimore, Maryland, the company also has a CLIA-certified laboratory in Greensboro, North Carolina.Ameritox offers urine drug testing and reporting services to help physicians determine if their chronic pain patients are taking their pain medications correctly. Physicians use this information to identify potential medication misuse and abuse, and make more informed decisions. Ameritox’s customer service and patient management support tools permit physicians to integrate medication monitoring into their practice. Wikipedia.


Time filter

Source Type

Patent
Ameritox | Date: 2016-07-29

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to Haldol therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.


The present disclosure provides methods of hydrolyzing a drug-glucuronide conjugate, and methods of determining a drug concentration comprising hydrolyzing a drug-glucuronide conjugate in the presence of a water miscible organic solvent that can simultaneously prevent bacterial growth in the enzyme and prevent analyte adsorption.


Patent
Ameritox | Date: 2014-12-11

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to lurasidone therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia.


Methods for helping to monitor subject adherence with a prescribed antipsychotic drug treatment regimen are disclosed.


Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.


Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population.


Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In an embodiment, the method comprises measuring a drug or metabolite level in urine of a subject and normalizing the measured drug or inverse of the metabolite level as a function of one or more parameters associated with the subject followed by transformation of the normalized data using the natural log of the normalized data. Embodiments of the methods use patient derived parameters together with the prescribed dose to affect a normalized and transformed value that can be compared to a normalized and transformed standard distribution derived from a body of collected urine fluid test results.


Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In an embodiment, the method comprises measuring a drug and a metabolite level in fluid of a subject and transforming the ratio of the measured drug levels and comparing the subsequent Drug Ratio with a likewise transformed Data Set of drug/metabolite ratios. Using the transformed ratio of parent drug to metabolite eliminates the need for further adjustments using patient specific parameters and other transforming/normalizing quantities.


Patent
Ameritox | Date: 2015-08-11

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to quetiapine therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia, bipolar disorder or major depressive disorder.


Methods for helping to monitor subject adherence with a prescribed antipsychotic drug treatment regimen are disclosed.

Loading Ameritox collaborators
Loading Ameritox collaborators